A stronger chelation for a superior theranostic : the preclinical study of 64Cu-DOTHA2-PSMA in prostate cancer animal model

Conclusions: 64Cu-DOTHA2-PSMA can be synthesized faster and more easily than 64Cu-DOTA-PSMA, while also being more stable. Provisional results predicted 64Cu-DOTHA2-PSMA’s pertinence for imaging and therapy. This radiotracer permits the use of an isotope with a longer half-life than 68Ga for potentially better PET imaging while also being available in Canada for therapy, in opposition to 177Lu. This could offer better PC metastasis diagnosis and treatment for patients. With this preclinical study, we aim to confirm ability to produce images of PC metastases. We also aim to provide evidence, in a pre-clinical model, of the therapeutic potential of 64Cu-DOTHA2-PSMA.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Oncology & amp; Translational (Poster Session) Source Type: research